Thierry Hercend

Thierry Hercend is currently an Independent Non-Executive Director at Inotrem SA, Director at Grey Wolf Therapeutics Ltd., Director at U3 Pharma AG, Venture Partner at Andera Partners SCA since 2006, and General Manager at GamaMabs Pharma SA since 2021.
Former roles include Chairman at Poxel SA, Chairman-Supervisory Board at Cytomics Pharmaceuticals SA and Genticel SA, Scientific Director-Healthcare Division at Roussel Uclaf SA, Director at Oncoethix GmbH and Complix NV, Vice President-Research at Vertex Pharmaceuticals, Inc. from 1998 to 2002, Vice President at Aventis SA from 2002 to 2005, Professor-Immunology at Université de Paris XI Paris Sud, Principal at Laboratoire Français du Fractionnement et des Biotechnologies, Head-Hemato-Immunology Unit at Institut de Formation Supérieure BioMédicale, and Head-Hemato Immunology Unit at Institut Gustave Roussy EURL.
Education includes a doctorate from Université Paris 1 Panthéon-Sorbonne.